Theratechnologies up as FDA agrees to amended protocol for tumor drug trial

Theratechnologies

02/06/2023 17:51

** U.S.-listed shares of Canadian biopharma co
Theratechnologies Inc  THTX.O  rise 11% to $0.96
    ** Co says FDA has agreed to its amended protocol for
early-stage study of drug candidate for treating tumors
    ** The announcement marks lifting of FDA's partial clinical
hold on the trial - THTX
    ** THTX had filed the amended trial protocol last month
after voluntarily pausing patient recruitment in Dec 2022 
    ** Co had proposed change in the frequency of administration
to weekly dosing and narrowing of patient population to focus on
those with high-grade serous ovarian cancer, high-grade cancer
in fallopian or endometrium
    ** Stock up 65% in last 12 months

 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))